Kezar Life Sciences is a biotechnology company that develops small molecule therapeutics to treat immune-mediated diseases and cancer. Its lead product candidate, KZR-616, is in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, and Phase 1b clinical trials for other related conditions. The company also has preclinical products in development, including KZR-261 and KZR-TBD.